Eli Lilly & Co. (NYSE: LLY) and Adocia announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE